As for HCQ, it can transfer the technology to manufacture to its US site, but would take a call depending on demand. As of now Lupin is prioritising Azithromycin and Albuterol.
It has made significant progress with its application for Albuterol with the US Food and Drug Administration (USFDA). "We made progress on the application with the agency (USFDA) and hope to get approval soon," said Gupta. There is demand for the product which has an estimated $1 billion market size in the US.
These apart, Generic Tamiflu (Oseltamivir), which is used to treat influenza A and B, too, is witnessing good offtake in the US market and Lupin is focusing on that as well. The demand for these drugs
has gone up 20-40 per cent. For Azithromycin, the demand has nearly tripled.
Lupin is also looking at its portfolio of anti-infectives, antivirals as well as the tuberculosis portfolio. "We are trying to determine which product might have activity in Covid-19," said Gupta.
Lupin will also track products that are being studied for use in Covid-19 and see if it can participate in that product, based on the outcome of these studies. Currently, repurposed drugs
like Remdesivir and Favipiravir are undergoing clinical trials in various parts of the globe.
Sun Pharmaceutical Industries has indicated it would soon start trials on Nafamostat, an anti-blood clotting and anti-inflammatory drug.
In India, domestic demand has taken a hit for Indian pharma. Gupta explained that in March there was surge in demand for chronic products that people were panic buying. This was followed by a significant dip in April as the doctor office visits had came down. In some therapy areas it came down 80 per cent. She expects demand to pick up in June-July, when demand is expected to be back to pre-Covid-19 days, which is also going to coincide with the flu season.